1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
M-J. Ahn, Jiaxin Niu, Dongwook Kim, Drew Rasco, Kathryn F. Mileham, Hyun Cheol Chung, Ulka N. Vaishampayan, Corinne Maurice‐Dror, Piere Russo, Talia Golan, Elliot Chartash, D. Chen, Jane Healy, Mohini Rajasagi, D.H. Lee
Topics & Concepts
MedicinePembrolizumabRashTolerabilityAdverse effectRefractory (planetary science)Internal medicineOncologyNauseaCancerImmunotherapyAstrobiologyPhysicsCancer Immunotherapy and BiomarkersCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research